Under the terms of the agreement, Roche will provide R&D funding and milestone payments, and Entelos will conduct biosimulation research using its Metabolism PhysioLab platform, which utilizes a 'virtual patient' approach to predict the effects of a drug on metabolic pathways and/or biomarkers. This approach will be useful to Roche in analyzing existing preclinical and clinical data in order to optimize future clinical trials.
The Entelos technology will be applied across several research programs and is expected to contribute information along the discovery and development path; from compound optimization through to clinical trial design.
“As part of this commitment, we believe Entelos' biosimulation capabilities and disease knowledge will complement Roche's expertise in metabolic diseases and provide us with cutting edge technology that will enhance our drug discovery programs,” said Jacques Mizrahi, global head of metabolic and vascular diseases at Roche.
Financial terms of the collaboration were not disclosed.